KOSDAQBiotech & Pharma359090

C&R Research

₩2,630▲ 13.85%2026-11-18 close
Market Cap
₩30.2B
Turnover
₩400M
Volume
150K
Shares out.
11.5M
PER
7.5×
PBR
0.4×
EPS
₩259
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Prices as of the 2026-11-18 close

01

Report overview

C&R Research: Sales Growth Versus Profit Recovery

C&R Research grew sales for three straight years through 2025 even as its operating margin fell from 11.3% in 2023 to 2.1% in 2025, and quarterly operating profit has been positive since the second quarter of 2026.

  1. 1

    Sales rose from KRW 48.5 billion in 2022 to KRW 65 billion in 2025, while operating profit fell from KRW 6.23 billion in 2023 to KRW 1.38 billion in 2025.

  2. 2

    After an operating loss of KRW 974 million in Q1 2026, operating profit was KRW 176 million in Q2 and KRW 2.2 billion in Q3.

  3. 3

    Backlog stood at KRW 160.1 billion at the end of June 2026, about 2.5 times 2025 sales, and cumulative new orders through Q3 2026 of KRW 75 billion were the largest on record, the company said.

  4. 4

    Operating cash flow turned to -KRW 3.07 billion in 2025 from a KRW 2.84 billion inflow in 2024.

  5. 5

    In April 2026 the company was reported to have received a notice of designation as an unfaithful-disclosure company over a supply-contract disclosure lapse.

02

Business structure

C&R Research is a contract research organization (CRO) that designs, runs and manages data for clinical trials on behalf of drug developers, and its core CRO business drives most of its results, according to BizWatch.

The Bio Times reported in October 2026 that the company has more than 500 staff and more than 2,800 completed clinical trials.

On a consolidated basis, five unlisted subsidiaries split the functions across the trial lifecycle, including a site management organization (SMO), C&R Research US and C&R Healthcare Global, an imaging-based trial platform and a sample analysis unit, according to Daily Pharm.

In January 2026 the company paid KRW 4.8 billion for a 52.39% controlling stake in a healthcare data software company, which it is using as the base for its data CRO business, according to Edaily.

Its client base has shifted from financially weaker biotech ventures toward large pharmaceutical companies with stronger cash flow, Edaily reported. Overseas revenue is still small: multi-country research projects generated KRW 9.5 billion in 2025, about 14.6% of total sales, according to Money Today.

A roughly KRW 11.5 billion multi-country Phase 3 contract with Daewoong Pharmaceutical, run in Korea and Indonesia in parallel, was reported in April 2026.

In competitive terms, CareerAidHub ranked the company 47th in its 2026 Top 50 Global CROs list and 15th in its APAC list, while IQVIA, ICON and Parexel led the top tier.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15.8B₩200M1.6%
2025Q4₩15.2B₩92,635,7530.6%
2026Q1₩14.8B-₩1B−6.6%
2026Q2₩17.8B₩200M1.0%
2026Q3₩19.3B₩2.2B11.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩48.5B₩4.7B₩3.9B9.7%10.9%95.5%
2023₩55.1B₩6.2B₩5.6B11.3%13.2%83.2%
2024₩59.7B₩3.6B₩3.8B6.1%8.2%81.8%
2025₩65B₩1.4B₩2.6B2.1%5.2%76.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales were KRW 48.5 billion in 2022, KRW 55.1 billion in 2023, KRW 59.7 billion in 2024 and KRW 65 billion in 2025, rising for three consecutive years from 2023 through 2025, with 2025 the largest year in the 2022–2025 span.

Operating profit moved from KRW 4.71 billion in 2022 to a peak of KRW 6.23 billion in 2023 (up 32.4% year on year), then fell to KRW 3.63 billion in 2024 (down 41.8%) and KRW 1.38 billion in 2025 (down 61.9%), declining for two consecutive years.

Operating margin went from 9.7% in 2022 to 11.3% in 2023, 6.1% in 2024 and 2.1% in 2025, so sales growth did not translate into margin improvement.

Net income attributable to controlling shareholders fell from KRW 5.56 billion in 2023 to KRW 3.84 billion in 2024 and KRW 2.59 billion in 2025, while net income including non-controlling interests was KRW 1.02 billion in 2025.

Daily Pharm attributed the 2025 profitability adjustment to overseas infrastructure expansion and system upgrade costs, along with the cost of consolidating subsidiaries.

The company cited the weaker domestic CRO market, delayed collection of receivables from some clients and heavier global investment as reasons for the margin decline, according to Money Today.

Operating cash flow went from KRW 2.52 billion in 2022, KRW 3.51 billion in 2023 and KRW 2.84 billion in 2024 to -KRW 3.07 billion in 2025. EBN reported that contract assets stood at KRW 21.4 billion at the end of 2025 and that short-term borrowings rose from KRW 705 million in 2024 to KRW 6.645 billion in 2025.

By quarter, sales were KRW 15.8 billion in Q3 2025, KRW 15.2 billion in Q4 2025 and KRW 14.8 billion in Q1 2026, then rose to KRW 17.8 billion in Q2 and KRW 19.3 billion in Q3 2026, increasing for two consecutive quarters.

Operating profit was KRW 246 million in Q3 2025 and KRW 92.64 million in Q4 2025, then turned to an operating loss of KRW 974 million in Q1 2026 before returning to a profit of KRW 176 million in Q2 and KRW 2.2 billion in Q3.

The Bio News reported that the company attributed the second-quarter turnaround to a recovery in the profitability of its core CRO business, while noting that R&D spending had partly limited consolidated profitability.

Net income attributable to controlling shareholders over the last four quarters, from Q4 2025 to Q3 2026, totaled KRW 2.98 billion.

05

Industry analysis

The domestic CRO market is in a phase of weaker demand, as pharmaceutical and biotech R&D budgets have contracted, according to Daily Pharm, which noted that the company still expanded its sales in that environment. Money Today reported that the company blamed the weaker domestic CRO market for the 2025 margin decline.

Demand for multi-country trials is rising, and the company is using its US, Thai, Singaporean and Indonesian bases to widen overseas order intake. Inbound global projects rose from 8 in 2024 and 11 in 2025 to 6 in the first half of 2026, according to BizWatch.

On the data side, independent research house JI Research argues that demand for data CRO services is growing as AI extends from drug candidate discovery into trial design and data management. In cycle terms, the company is shifting from reliance on domestic R&D toward overseas orders.

Among competitors, IQVIA, ICON and Parexel lead the global rankings, and C&R Research placed 47th globally and 15th in the APAC ranking for 2026.

The Bio Times reported that the ranking body described its direct overseas operating scale and independently verifiable multi-country trial scope as still expanding relative to some larger CROs.

06

Outlook

The company has reportedly raised its new-order target to KRW 120 billion and set a goal of becoming a Global Top 20 CRO, according to a Seoul Economic Daily report.

Cumulative new orders through Q3 2026 reached KRW 75 billion, the largest on record, with KRW 21.1 billion, about 28%, from overseas, according to The Bio News.

Multi-country trial-related revenue in the first half of 2026 was about KRW 5 billion, and tax-invoice billings reached KRW 4.53 billion, about 2.3 times the KRW 1.98 billion of a year earlier, according to BizWatch.

BizWatch expects the contribution to results to grow gradually as new orders move into project execution and revenue recognition. The company said its healthcare data subsidiary signed a supply agreement with the US firm OneMedNet to strengthen its data and AI services.

Independent research house JI Research projected 2026 standalone sales of KRW 67 billion and operating profit of KRW 5.1 billion, a forecast reported in July 2026.

ARIS projected 2026 sales of KRW 70 billion and operating profit of KRW 4.5 billion, and said the company could enter a growth phase from the second half, in a report dated July 2026.

These forecasts can be compared with the disclosed quarterly results, which show an operating loss of KRW 974 million in Q1 2026, KRW 176 million in Q2 and KRW 2.2 billion in Q3.

The Q4 2026 results have not yet been released, and whether full-year operating profit reaches the level of these forecasts is the next point to watch.

07

Valuation

PER
7.5×
PBR
0.4×
ROE
5.9%
EPS
₩259
BPS
₩4,468
Dividend per share
—

Valuation interpretation depends on how far earnings recover. The price-to-book ratio is below 1x, meaning the stock trades below its net asset value. The share price fell sharply over the past year, according to investing.com data.

Operating profit and net income attributable to controlling shareholders declined from the 2023 peak through 2025, and the direction changed with the return to operating profit in Q2 2026 and the rise in Q3 profit.

Because net income attributable to controlling shareholders totaled only KRW 2.98 billion over the last four quarters, earnings-based multiples can move sharply on the results of a single quarter.

ARIS said that if order growth and profitability improvement coincide, there is a possibility of a revaluation of the company's value. An industry analyst cited in a May 2026 report said the stock's discount could persist if overseas investment does not produce high-margin contracts.

A 5-to-1 share consolidation took place in March 2026, so per-share metrics should be compared on a post-consolidation basis, and the company has cited cash dividends and share consolidation as ways to raise shareholder value.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Backlog and new orders

Total contract value stood at KRW 370.5 billion and the backlog at KRW 160.1 billion at the end of June 2026, about 2.5 times 2025 sales, according to BizWatch. Cumulative new orders through Q3 2026 reached KRW 75 billion, the largest on record, with KRW 21.1 billion from overseas, per The Bio News.

Because CRO revenue is recognized over the course of each project, the higher backlog is presented as a basis for medium-term revenue visibility.

Quarterly profit turned positive in 2026

Operating profit moved from a KRW 974 million loss in Q1 2026 to KRW 176 million in Q2 and KRW 2.2 billion in Q3. Q3 2026 sales were KRW 19.3 billion, up 22.2% from a year earlier. The company attributed the second-quarter turnaround to a recovery in profitability of its core CRO business, according to The Bio News.

Growing inbound global projects

Inbound global projects rose from 8 in 2024 and 11 in 2025 to 6 in the first half of 2026 alone, according to BizWatch. Multi-country trial-related billings in the first half of 2026 were KRW 4.53 billion, about 2.3 times the KRW 1.98 billion of a year earlier.

The company formed a partnership with Equilab International in January 2026 and set up an Indonesian unit in March, according to Money Today.

09

Bear factors

Falling operating margin

Operating margin fell from 11.3% in 2023 to 6.1% in 2024 and 2.1% in 2025. Operating profit declined for two consecutive years, and net income including non-controlling interests was KRW 1.02 billion in 2025. Daily Pharm attributed the drop to overseas infrastructure expansion and system-building costs. The core bearish point is that sales growth has not yet translated into margin recovery.

Cash conversion and contract assets

Operating cash flow was -KRW 3.07 billion in 2025 after a positive KRW 2.84 billion in 2024. EBN reported contract assets of KRW 21.4 billion at the end of 2025 and explained that they represent services performed but not yet billed or collected.

Short-term borrowings rose from KRW 705 million in 2024 to KRW 6.645 billion in 2025 while cash and cash equivalents declined. The gap between recognized earnings and cash inflow is the main bearish factor.

Possible return to quarterly losses

Q1 2026 recorded an operating loss of KRW 974 million and a net loss attributable to controlling shareholders of KRW 324 million. Profit returned in Q2 and Q3, but earnings remain small, so a single quarter can move the margin sharply. Net income attributable to controlling shareholders from Q4 2025 through Q3 2026 totaled KRW 2.98 billion.

10

Risk factors

Disclosure and listing

EBN reported in April 2026 that the company received a notice of designation as an unfaithful-disclosure company over a supply-contract disclosure lapse and a contract-value change above 50 percent.

Depending on accumulated penalty points, final designation could lead to trading suspension or a listing-eligibility review. A 5-to-1 share consolidation was carried out in March 2026.

Client collections

Money Today reported that the company cited delayed collection of receivables from some clients as one factor behind the 2025 margin decline. EBN noted that CRO revenue is recognized stage by stage, while cash collection can come only after project completion or milestones. Whether the shift toward large pharma clients reduces this risk will show up in future operating cash flow.

Overseas expansion and market conditions

The domestic CRO market has weakened as pharmaceutical and biotech R&D budgets contracted, according to Daily Pharm. Staffing and regulatory-system costs arise before overseas revenue when new subsidiaries are set up, which can dilute profitability, EBN reported. If overseas investment does not yield high-margin contracts, margin recovery could take longer.

11

What to watch next

  1. By March 31, 2027

    Deadline for the 2026 annual report, the next regular filing. The key checks are whether the operating margin recovers from 2.1% in 2025 and whether the quarterly profit trend from Q2 2026 holds on a full-year basis.

  2. Around February 2027 (expected)

    Expected timing for the Q4 2026 results. Because the quarter has no regular filing yet, provisional figures will come first, and the key point is whether operating profit holds near the KRW 2.2 billion of Q3 2026.

  3. By May 15, 2027

    Deadline for the Q1 2027 quarterly report. The comparison with the KRW 974 million operating loss of Q1 2026, and the pace at which global contracts convert into revenue, are the key points.

12

Overall view

C&R Research's sales rose from KRW 48.5 billion in 2022 to KRW 65 billion in 2025, but operating profit fell from KRW 6.23 billion in 2023 to KRW 1.38 billion in 2025, so top-line growth and profitability have diverged.

Operating cash flow turned negative at -KRW 3.07 billion in 2025, and rising contract assets and short-term borrowings widened the gap between earnings and cash. In 2026, an operating loss in Q1 was followed by profits in Q2 and Q3, with Q3 operating profit at KRW 2.2 billion.

A backlog of KRW 160.1 billion at the end of June 2026 and cumulative new orders of KRW 75 billion through Q3 2026 are cited as supporting medium-term revenue visibility.

On the other side, the April 2026 notice of designation as an unfaithful-disclosure company, the weaker domestic CRO market and the upfront cost of overseas investment are the main bearish factors.

JI Research and ARIS projected 2026 sales of KRW 67 billion and KRW 70 billion and operating profit of KRW 5.1 billion and KRW 4.5 billion, and comparing those figures with the Q4 2026 and annual reports is the next checkpoint.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. medipana.com
  2. thebionews.net
  3. news.bizwatch.co.kr
  4. dailypharm.com
  5. thebionews.net
  6. cnrres.co.kr
  7. mt.co.kr
  8. ebn.co.kr
  9. pharm.edaily.co.kr
  10. investing.com
  11. thebionews.net
  12. m.news.nate.com
  13. v.daum.net
  14. judal.co.kr
  15. thebionews.net
  16. judal.co.kr
  17. judal.co.kr
  18. biotimes.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis